Related Experiment Videos
Rosiglitazone and heart failure: long-term vigilance
1Department of Endocrinology and Metabolism, Veterans Affairs Puget Sound Healthcare System, Medicine-111, 1660 South Columbian Way, Seattle, WA 98108, USA. Nalini.Singh2@med.va.gov
Journal of Cardiovascular Pharmacology and Therapeutics
|April 20, 2004
Summary
Thiazolidinediones improve glycemic control but can lead to congestive heart failure with long-term use. Early detection and withdrawal of rosiglitazone are crucial for patient recovery.
Area of Science:
- Endocrinology
- Cardiology
Background:
- Thiazolidinediones are effective in improving insulin resistance and glycemic control.
- Short-term studies show significant benefits without adverse effects.
Observation:
- Peripheral edema and congestive heart failure (CHF) can occur in long-term thiazolidinedione therapy.
- Two patients developed CHF 6-12 months after starting rosiglitazone with insulin.
Findings:
- Rosiglitazone initially improved glycemic control in both patients.
- CHF symptoms resolved after diuretics, afterload reduction, and rosiglitazone withdrawal.
Implications:
- Healthcare providers must monitor for CHF in patients on long-term thiazolidinediones, especially those with comorbidities.
- Early recognition and management, including drug withdrawal, are key to reversing CHF in these patients.